Aim: To compare real-world effectiveness/safety of non-vitamin K antagonist oral
anticoagulants and vitamin K antagonists among patients with non-valvular atrial fibrillation …

Introduction: Choosing between different non-vitamin K antagonist oral anticoagulants
(NOACs) in non-valvular atrial fibrillation (NVAF) is difficult due to the absence of head to …

Background Stroke is the most serious clinical consequence of atrial fibrillation, which is the
most common cardiac arrhythmia. Non-vitamin K antagonist oral anticoagulants (NOACs) …

Objectives. We conducted a systematic review and network meta-analysis of randomized
controlled trials (RCTs) including the comparison of non-vitamin K antagonist oral …

Introduction: Several comparative real-world effectiveness studies on direct oral
anticoagulants (DOACs) have been conducted, but an overview of the available evidence …

Background: In randomized controlled trials (RCTs) direct acting oral anticoagulants
(DOACs) showed a superior risk-benefit profile in comparison to vitamin K antagonists …

Introduction: Numerous real-world studies have compared non-vitamin K antagonist oral
anticoagulants (NOACs) with vitamin K antagonists (VKAs) in patients with non-valvular …

The non-vitamin K antagonist oral anticoagulants (NOACs) have been increasingly
prescribed in clinical practice for stroke prevention in patients with nonvalvular atrial …

Aims The well-known limitations of vitamin K antagonists (VKA) led to development of new
oral anticoagulants (NOAC) in non-valvular atrial fibrillation (NVAF). The aim of this meta …

The novel oral anticoagulants (NOACs) apixaban, dabigatran, and rivaroxaban have been
recently indicated for stroke prevention in patients with atrial fibrillation (AF). Due to a lack of …